BJU Int

1. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
   Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
   BJU Int. 2024;133:548-554.
   

   >> Share

   
   
2. GRAJALES V, Martini A, Shore ND
   Complications of immuno-oncology care: what urologist should know.
   BJU Int. 2024;133:524-531.
   

   >> Share

   
   
3. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
   Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
   BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
   

   >> Share

   
   

   
   BMC Cancer

4. COLETTA AM, Simon LH, Maslana K, Taylor S, et al
   Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
   BMC Cancer. 2024;24:493.
   

   >> Share

   
   

   
   BMC Urol

5. WANG Z, Wang X, Yu X
   The effects of different positions on lower extremity hemodynamics during robot-assisted laparoscopic radical prostatectomy for prostate cancer.
   BMC Urol. 2024;24:92.
   

   >> Share

   
   

   
   Cancer Res

6. SHRESTHA RK, Nassar ZD, Hanson AR, Iggo R, et al
   ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis.
   Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-1489.
   

   >> Share

   
   

   
   Curr Treat Options Oncol

7. FANG AM, Jackson J, Gregg JR, Chery L, et al
   Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.
   Curr Treat Options Oncol. 2024 Apr 20. doi: 10.1007/s11864-024-01208.
   

   >> Share

   
   

   
   Eur Radiol

8. CAGLIC I, Sushentsev N, Syer T, Lee KL, et al
   Biparametric MRI in prostate cancer during active surveillance: is it safe?
   Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10770.
   

   >> Share

   
   

   
   Eur Urol

9. SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
   Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
   Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
10. HINDIE E, Champion C, Morgat C
    Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
    Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
11. CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
    Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
    Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Int J Cancer

12. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    

    >> Share

    
    

    
    J Clin Oncol

13. EKANGER C, Helle SI, Reisaeter L, Hysing LB, et al
    Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
    J Clin Oncol. 2024 Apr 23:JCO2301391. doi: 10.1200/JCO.23.01391.
    

    >> Share

    
    

    
    J Nucl Med

14. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    

    >> Share

    
    
15. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    

    >> Share

    
    

    
    Mod Pathol

16. FERRERO A, Ghelichkhan E, Manoochehri H, Ho MM, et al
    HistoEM: A Pathologist-Guided and Explainable Workflow Using Histogram Embedding for Gland Classification.
    Mod Pathol. 2024;37:100447.
    

    >> Share

    
    

    
    Oncogene

17. RAWAT C, Heemers HV
    Alternative splicing in prostate cancer progression and therapeutic resistance.
    Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
    

    >> Share

    
    

    
    Prostate

18. NGUYEN AM, Carter GC, Wilson LM, Canfield S, et al
    Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score(R) (GPS(TM)) assay.
    Prostate. 2024 Apr 26. doi: 10.1002/pros.24709.
    

    >> Share

    
    
19. CHARLTON PV, O'Reilly D, Philippou Y, Rao SR, et al
    Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
    Prostate. 2024 Apr 23. doi: 10.1002/pros.24715.
    

    >> Share

    
    
20. KAREGAR-NIAVOL R, Ghaffari F, Saravi A, Fotokian Z, et al
    Translation and validation of a lifestyle questionnaire related to prostate cancer.
    Prostate. 2024 Apr 21. doi: 10.1002/pros.24713.
    

    >> Share

    
    
21. MARSHALL CH, Gondek LP, Daniels V, Lu C, et al
    Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
    Prostate. 2024 Apr 20. doi: 10.1002/pros.24712.
    

    >> Share

    
    
22. DONG Q, Wang C, Shen D, Ma Y, et al
    Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
    Prostate. 2024;84:780-787.
    

    >> Share

    
    
23. BUTTNER T, Gartner F, Essler M, Weiten R, et al
    Key learnings from concordant systematic biopsies in prostate-specific membrane antigen positron emission tomography/computed tomography-guided prostate biopsies: Enhancing targeting accuracy.
    Prostate. 2024;84:772-779.
    

    >> Share

    
    
24. FLETCHER SA, Mamawala MM, Holler AE, Bhanji Y, et al
    Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
    Prostate. 2024;84:723-730.
    

    >> Share

    
    
25. BENNETT R 4TH, Li EV, Ho AY, Aguiar JA, et al
    Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
    Prostate. 2024;84:717-722.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

26. VERMA Y, Perera Molligoda Arachchige AS
    Advances in Tumor Management: Harnessing the Potential of Histotripsy.
    Radiol Imaging Cancer. 2024;6:e230159.
    

    >> Share

    
    

    
    Urology

27. KLAASSEN Z, Kyle Cline J, Sayyid RK
    Editorial Comment on "Major Complications and Adverse Events Related to use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy".
    Urology. 2024 Apr 20:S0090-4295(24)00274-7. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share